ALHC vs. AZN: A Head-to-Head Stock Comparison
UpdatedHere’s a clear look at ALHC and AZN, comparing key factors like performance, valuation metrics, dividends, and financial strength. It’s built for investors or anyone curious to see how these two stocks match up.
Company Overview
AZN stands out with 432.07 billion USD in market value—about 142.46× ALHC’s market cap of 3.03 billion USD.
ALHC’s beta of 1.33 points to much larger expected swings compared to AZN’s calmer 0.18, suggesting both higher upside and downside potential.
AZN is an ADR, letting U.S. buyers tap its non-U.S. business directly, unlike ALHC, which is purely domestic.
| Symbol | ALHC | AZN |
|---|---|---|
| Company Name | Alignment Healthcare, Inc. | AstraZeneca PLC |
| Country | US | GB |
| Sector | Healthcare | Healthcare |
| Industry | Medical - Healthcare Plans | Drug Manufacturers - General |
| CEO | Mr. John E. Kao | Mr. Pascal Claude Roland Soriot D.V.M., M.B.A. |
| Price | 15.33 USD | 69.68 USD |
| Market Cap | 3.03 billion USD | 432.07 billion USD |
| Beta | 1.33 | 0.18 |
| Exchange | NASDAQ | NASDAQ |
| IPO Date | March 26, 2021 | May 12, 1993 |
| ADR | No | Yes |
Performance Comparison
This chart compares the performance of ALHC and AZN over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).
Hover over the lines to see the investment’s value and total return (%) at specific dates.
Data is adjusted for dividends and splits.
Valuation Metrics Comparison
The section examines key financial ratios to assess the valuation of ALHC and AZN based on earnings, cash flow, sales, and book value. Pay attention to the following notable points where extreme values stand out.
- ALHC posts a negative P/E of -32.75, reflecting last year’s net loss, while AZN at 27.80 signals healthy earnings.
- ALHC posts a negative forward PEG of -1.11, hinting at anticipated earnings decline, whereas AZN at 2.50 has projections for stable or growing earnings.
| Symbol | ALHC | AZN |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | -32.75 | 27.80 |
| Forward PEG Ratio (TTM) | -1.11 | 2.50 |
| Price-to-Sales Ratio (P/S, TTM) | 1.01 | 3.93 |
| Price-to-Book Ratio (P/B, TTM) | 27.45 | 5.26 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | 159.00 | 22.33 |
| EV-to-EBITDA (TTM) | -64.47 | 13.68 |
| EV-to-Sales (TTM) | 0.86 | 4.41 |
| EV-to-Free Cash Flow (TTM) | 136.01 | 25.07 |
Dividend Comparison
ALHC offers a 0% dividend yield, suggesting it may be reinvesting available cash back into the business for future growth, while AZN provides a 1.39% dividend yield, giving investors a steady income stream.
| Symbol | ALHC | AZN |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 1.39% |
Financial Strength Metrics Comparison
This section dives into the financial resilience of ALHC and AZN, spotlighting key metrics like liquidity, leverage, and debt coverage. Check out the standout observations below where notable differences or extremes pop up.
- AZN’s current ratio of 0.90 indicates its assets may not cover near-term debts, whereas ALHC at 1.69 maintains healthy liquidity.
- AZN posts a quick ratio of 0.70, indicating limited coverage of short-term debts from its most liquid assets—while ALHC at 1.69 enjoys stronger liquidity resilience.
- With negative EBIT (-2.98), ALHC cannot cover its interest payments. AZN, with an interest coverage of 7.95, meets its interest obligations.
| Symbol | ALHC | AZN |
|---|---|---|
| Current Ratio (TTM) | 1.69 | 0.90 |
| Quick Ratio (TTM) | 1.69 | 0.70 |
| Debt-to-Equity Ratio (TTM) | 0.07 | 0.77 |
| Debt-to-Assets Ratio (TTM) | 0.01 | 0.30 |
| Interest Coverage Ratio (TTM) | -2.98 | 7.95 |